Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility The FDA has granted commercial licensure approval for Novartis' Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma®, as well as produce…..
License Option Agreement with Pfizer for Voyager Therapeutic's Next-Generation TRACERᵀᴹ AAV Capsids Voyager Therapeutics, a gene therapy company developing adeno-associated virus (AAV) platform technologies, announced an agreement through which Pfizer may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of…..
New study expands evaluation of gene therapy for spinal muscular atrophy German researchers have just published results of a retrospective analysis of routine data collected from all patients with spinal muscular atrophy (SMA) treated with Zolgensma® (onasemnogene abeparvovec - adeno-associated viral (AAV9) vector-based gene therapy that introduces a functional copy…..
Vector-Based Gene Therapy and Gene-Editing Products Ongoing Clinical Trials Gene therapies are now a reality. They open new perspectives for the treatment and management of a wide range of rare and common diseases. We have listed ongoing clinical trials using viral vector and gene editing products to get a more…..
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their latest report:"AAV-based gene therapy Products: Ongoing Clinical Trials". This 205-page report provides you with a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More than 80 products from 49…..
FEATURE STORY ● Artificial intelligence approach to create AAV capsids for gene therapies DISRUPTIVE TECHNOLOGIES ● Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier CLINICAL TRIALS - DATAS ● Libella gene therapeutics to run a patient paid trial of telomerase gene therapy M&A - AGREEMENTS ●…..
Two Chinese companies invest in Vigeneron, a German firm developing ophthalmological gene therapy programs The German gene therapy company Vigeneron has closed a series A financing round led by WuXi AppTec, a Chinese provider of R&D and manufacturing services and Sequoia Capital China, a venture capital firm based in Beijing.…..
More than 580 gene therapy products are under development in biotech and pharmaceutical companies for the treatment of more than 240 diseases. More than 200 of these products are now at the clinical stage. After releasing our « Landscape in… Gene Therapy Companies » in September, we now offer you an opportunity…..
Gene Therapy is a rapidly and obviously evolving field that is now definitively recognized as a well-acknowledged major medical and scientific area. BioPharmAnalyses is proud to announce the launch of its new global commercial report "Landscape in Gene Therapy Companies". This is the first such report that provides you with an actually updated information and an accurate international mapping…..
